Related Experiment Video
Updated: Sep 26, 2026
13:34
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research
1Department of Biology, Wheaton College, Wheaton, IL 60187, USA. Roger.H.Kennett@wheaton.edu
Current Opinion in Molecular Therapeutics
|April 3, 2003
Abstract:
Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.
